S&P Futures Slip After 6 Straight Winning Sessions
Stock futures slipped early Tuesday, putting the S&P 500's six-day winning streak in jeopardy.Futures for the Dow Jones Industrials index gained eight points to 42,893Futures for the S&P 500 index settled 9.75 points, or 0.2%, to 5,972.75Futures for the NASDAQ faded 47.75 points, or 0.2%, to 21,479.75. Shares of Home Depot were trading 2% higher in Tuesday’s premarket hours, after the home improvement retailer stuck by its full-year guidance, expecting total sales for the full year to grow by 2.8%. CFO Richard McPhail also said the company doesn’t have any plans to raise prices in the face of higher tariffs.The moves in futures follow a relatively calm trading session on Monday that saw the S&P 500 grind higher by 0.09% for its sixth straight positive session. The Dow gained about 137 points, or 0.32%, while the NASDAQ Composite ticked up just 0.02%.While Monday’s gains were marginal, they do add to what has been a rapid and sharp rebound for stocks over the past five weeks. The S&P 500 is now just 3% from its record high.The gains came despite continued uncertainty around the impact of tariffs on the economy and worries about a potential U.S. recession. Investors even shrugged off the downgrade of the U.S. government’s credit by Moody’s Ratings.In Japan, the Nikkei 225 index edged up 0.1% Tuesday, while in Hong Kong, the Hang Seng progressed 1.5%. Oil prices dropped 14 cents to $62.55 U.S. a barrel. Gold prices hiked $7.50 to $3,241 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


